Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

(such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. The rise in incidence of CDI, along with high rates of both treatment failures and recurrences with current therapies has resulted in greater awareness and concern about CDI among medical professionals and public health officials. You may learn more about CDI at www.cdiinfo.org, a website of Optimer.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist's web site at www.cubist.com.

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic b
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... BD (Becton, Dickinson and Company) (NYSE: BDX ... of its third fiscal quarter 2011 earnings conference call on ... will issue a press release detailing the quarter,s earnings earlier ... along with related slides, will be accessible through BD,s website ...
... Va., July 8, 2011 The Amerigroup Foundation recently ... the Rx Partnership to benefit the Rockbridge Area Free ... organization that works to provide uninsured Virginians with access ... broker to access and distribute free bulk prescription medications ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2
(Date:7/9/2014)... Health Organization recommends that youth participate in a minimum ... (MVPA) each day. Studies have shown that youth ... Therefore, it stands to reason that increasing outdoor time ... new study scheduled for publication in The Journal ... after school was positively associated with MVPA. , Drs. ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... findings from Fox Chase Cancer Center paint a relatively ... of breast cancers that have spread to the chest ... that grow into the skin, regardless of size and ... as stage III and called "locally advanced" tumors, ... cancer, often with poor survival. Locally advanced breast cancers ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2
... When patients choose to leave the hospital before the ... of inadequately treated medical conditions and the need for ... issue of Mayo Clinic Proceedings . Additionally, the ... predictors and potential interventions to help manage and improve ...
... in the international journal Chest , by Neil ... disease (COPD) who breathed a mix of 60% helium ... to exercise longer and harder than those who breathed ... significant because research has shown that patients who perform ...
... 2009Chemicals present in cranberriesand not the acidity of cranberry ... the cells that line the urinary tract, as documented ... Food , a peer-reviewed journal published by Mary Ann ... free online at www.liebertpub.com/jmf , Urinary tract ...
... Provide Information on Medicare Advantage Special Needs Plans, ... March 9 A series of free seminars ... illness maintain a healthy lifestyle and learn about ... unique needs will be offered during March at ...
... continued growthATLANTA, March 9 Reveille Software(TM) ... grown to 275 customers and expanded its ... itself for continued market growth in helping ... performance management.Reveille,s solution, Reveille Experience and Performance ...
... study show continued, significant relief of depressive symptoms, ... hospitalization and death among ESRD patientsLAWRENCE, Mass., March ... NXTM ), a leading manufacturer of innovative dialysis ... its ongoing FREEDOM study, which show that the ...
Cached Medicine News:Health News:Patients being discharged against medical advice 2Health News:Helium helps lung patients breathe easier 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Seminars Offered to Missouri Seniors With Diabetes and Other Chronic Illnesses 2Health News:Reveille Software Reaches Customer Milestone and Expands Executive Team 2Health News:Reveille Software Reaches Customer Milestone and Expands Executive Team 3Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 2Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 3Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 4
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... The SheerVision FireFly Infinity Light ... most technologically advanced LED light ever ... ,With the FireFly Infinity you'll get ... unrestricted mobility to go whereever your ...
... SICKLEDEX detects the presence of ... requires 2ml of reconstituted solubility buffer and ... of sickle cell hemoglobin control. Each test ... with Saponin, two buffer dispensing caps and ...
... is for use as a sheath fluid ... 70ml bottle of Cytometry Concentrate dilutes to ... Compared to Cubitainers, Streck Cytometry Concentrate reduces ... money without compromising performance. Streck Cytometry Concentrate ...
Medicine Products: